- Home
- BOLD vs DARE Comparison
BOLD vs DARE Comparison
Compare BOLD & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- DARE
- Stock Information
- Founded
- BOLD 2018
- DARE 2015
- Country
- BOLD United States
- DARE United States
- Employees
- BOLD N/A
- DARE N/A
- Industry
- BOLD
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- DARE Health Care
- Exchange
- BOLD Nasdaq
- DARE Nasdaq
- Market Cap
- BOLD 30.3M
- DARE 27.7M
- IPO Year
- BOLD 2024
- DARE N/A
- Fundamental
- Price
- BOLD $1.05
- DARE $2.82
- Analyst Decision
- BOLD Buy
- DARE Strong Buy
- Analyst Count
- BOLD 3
- DARE 3
- Target Price
- BOLD $4.00
- DARE $12.50
- AVG Volume (30 Days)
- BOLD 205.8K
- DARE 33.9K
- Earning Date
- BOLD 08-11-2025
- DARE 08-11-2025
- Dividend Yield
- BOLD N/A
- DARE N/A
- EPS Growth
- BOLD N/A
- DARE N/A
- EPS
- BOLD N/A
- DARE N/A
- Revenue
- BOLD N/A
- DARE $25,909.00
- Revenue This Year
- BOLD N/A
- DARE $99,756.91
- Revenue Next Year
- BOLD N/A
- DARE $119.77
- P/E Ratio
- BOLD N/A
- DARE N/A
- Revenue Growth
- BOLD N/A
- DARE N/A
- 52 Week Low
- BOLD $1.01
- DARE $2.67
- 52 Week High
- BOLD $6.24
- DARE $5.76
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- DARE 39.02
- Support Level
- BOLD N/A
- DARE $2.84
- Resistance Level
- BOLD N/A
- DARE $2.93
- Average True Range (ATR)
- BOLD 0.00
- DARE 0.13
- MACD
- BOLD 0.00
- DARE -0.03
- Stochastic Oscillator
- BOLD 0.00
- DARE 13.21
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.